Clinical Trials Logo

Lymphocele clinical trials

View clinical trials related to Lymphocele.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03791736 Terminated - Breast Cancer Clinical Trials

Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation

SANDOSTATINE
Start date: July 6, 2016
Phase: N/A
Study type: Interventional

The lymphocele is the main early postoperative complication of axillary clearance for breast cancer patients with rates up to 85%. The usual treatment consists of external drainage. However, this method increases the duration of hospitalization. As a result, some practitioners have abandoned drainage, allowing for ambulatory surgery. If this solution makes it possible to reduce the duration of the hospitalizations, it involves iterative punctures of the axillary hollow in case of lymphocele These punctures may be responsible for pain, hematoma or infection of the operative site. To date, no method has proved superior in terms of decreasing the incidence of lymphocele postoperatively axillary clearance. Octreotide (Sandostatin®) is a peptide, one of whose effects is to reduce the inflammation responsible for lymphoceles. The aim of the study is to inject Sandostatin® before surgery, with the aim of reducing the incidence of seroma by 50% after axillary clearance

NCT ID: NCT03006562 Terminated - Prostate Cancer Clinical Trials

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

PREVENTER
Start date: July 1, 2017
Phase: Phase 4
Study type: Interventional

The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous thromboembolism (VTE) after radical prostatectomy (RP).

NCT ID: NCT01644136 Terminated - Prostate Cancer Clinical Trials

Microspheres in Preventing Lymphatic Fluid Collection After Surgery in Patients With Prostate Cancer

Start date: July 14, 2011
Phase: N/A
Study type: Interventional

This study is being performed to investigate if the application of Arista absorbable hemostat (AH)®, a product approved to stop surgical bleeding, can prevent lymphoceles. Lymphoceles are collections of lymphatic fluid which can occur after a lymph node dissection for cancer. These fluid collections can become symptomatic in some patients. Arista would be applied to one side of the pelvis after a pelvic lymph node dissection, to see if this decreases the number of postoperative lymph fluid collections seen on a computed tomography (CT) scan after surgery